National Resilience

PartnerSlate is an online platform facilitating strategic partnerships between food and beverage brands and contract manufacturers across North America. It streamlines the manufacturing process by connecting brands with reliable production partners, reducing sourcing delays, and enabling efficient market scaling of new products.

Swiftscale Biologics is a healthcare service provider based in South San Francisco, California, founded in 2019. The company specializes in cell-free protein synthesis, focusing on rapid expression, high-throughput synthesis, and the production of complex proteins. Its innovative platform is designed to test and develop antibodies that inhibit the interaction between viral proteins and human host cells, effectively stopping ongoing coronavirus infections. By advancing these life-saving drugs, Swiftscale Biologics aims to enhance patient outcomes and improve overall health.

Cellevolve Bio is a development and commercialization company specializing in cell therapies aimed at neglected diseases. The company collaborates with innovators to transition early-stage clinical therapies into commercially available treatments, particularly for pediatric and rare diseases. By advancing these therapies into clinical development, Cellevolve aims to significantly enhance patient outcomes and provide expertise in cell therapy and clinical care.

Bit.bio specializes in applying computational principles to biology, focusing on developing a scalable platform capable of producing consistent batches of every human cell. This enables more accurate research, drug discovery, and cell therapy applications.

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to eliminate dependency on donor or patient cells for blood stem cell transplants, leveraging a platform technology that generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free, providing patients with rapid and broad access to durable therapies.

Ology Bioservices is an integrated biopharmaceutical company specializing in the development and manufacturing of biopharmaceutical products and medical devices. Founded in 1999 and restructured in 2017, the company operates as a contract development and manufacturing organization (CDMO), providing services that include preclinical and clinical development, formulation optimization, and cGMP manufacturing. Ology Bioservices supports a wide range of drug types, from small molecules to proteins and vaccines, enabling clients to access high-quality biopharmaceutical solutions efficiently and cost-effectively. The company is equipped to manufacture products in compliance with BSL-3 standards, ensuring that it can cater to various client needs within the biopharmaceutical sector.